Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting

SAN DIEGO, March 24, 2022 /PRNewswire/ — Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that data from INBRX-121 and INBRX-130 will be presented at the 2022 American Association for…

Click here to view original post